Share ownership Roche Holding AG Swiss Exchange

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:36 15/05/2026 BST			5-day change	1st Jan Change
322.80 ^CHF	+0.88%		-0.59%	-1.65%

09:02pm	Fda approves Genentech's Tecentriq for adjuvant muscle-invasive bladder cancer with ctDNA-guided treatment	RE
05:47pm	FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in some patients	RE

Share class: Roche Holding AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	106,691,000	29,265,503 ( 27.43 %)	0	88.75 %
Stock B	1	702,562,700	688,923,187 ( 98.06 %)	13,636,063 ( 1.941 %)

Major shareholders: Roche Holding AG

Name	Equities	%	Valuation
Sjunde AP-fonden 0.1602 %	1,125,554	0.1602 %	458 M CHF
State Street Global Advisors Ltd. 0.1558 %	1,094,361	0.1558 %	446 M CHF
DWS CH AG 0.1128 %	792,600	0.1128 %	323 M CHF
Baloise Asset Management AG 0.1063 %	746,545	0.1063 %	304 M CHF
Berner Kantonalbank AG (Investment Management) 0.0817 %	573,785	0.0817 %	234 M CHF
Basellandschaftliche Kantonalbank (Investment Management) 0.0778 %	546,553	0.0778 %	223 M CHF
AllianceBernstein Investments Taiwan Ltd. 0.0714 %	501,700	0.0714 %	204 M CHF
LLB Asset Management AG 0.0701 %	492,181	0.0701 %	200 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.0685 %	481,077	0.0685 %	196 M CHF
LUKB Expert Fondsleitung AG 0.0656 %	460,709	0.0656 %	188 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Aristotle Capital Management LLC 0.0375 %	2,107,960	0.0375 %	105 M CHF
Saratoga Research & Investment Management 0.023 %	1,291,630	0.023 %	64 M CHF
Boston Common Asset Management LLC 0.005735 %	322,354	0.005735 %	16 M CHF
Old National Bank (Investment Management) 0.004588 %	257,854	0.004588 %	13 M CHF
Hantz Financial Services, Inc. 0.003829 %	215,187	0.003829 %	11 M CHF
Altrius Capital Management, Inc. 0.003148 %	176,959	0.003148 %	9 M CHF
S & Co., Inc. 0.002501 %	140,551	0.002501 %	7 M CHF
Bard Financial Services, Inc. 0.002467 %	138,650	0.002467 %	7 M CHF
Port Street Investments LLC 0.002319 %	130,352	0.002319 %	6 M CHF
AEGON Investment Management BV 0.002318 %	130,284	0.002318 %	6 M CHF
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Hoffmann Family 64.71 %	69,044,895	64.71 %	28 835 M CHF
Maja Oeri 3.792 %	4,045,950	3.792 %	1 690 M CHF
Melchior Oeri 3.792 %	4,045,950	3.792 %	1 690 M CHF
Severin Schwan 0.2493 %	265,962	0.2493 %	111 M CHF
Towers Watson Investment Management Ltd. 0.1233 %	131,587	0.1233 %	55 M CHF
Scottish Widows Schroder Person Wealth (ACD) Ltd. 0.1167 %	124,560	0.1167 %	52 M CHF
zCapital AG 0.089 %	95,000	0.089 %	40 M CHF
Mirabaud Asset Management (Suisse) SA 0.0614 %	65,500	0.0614 %	27 M CHF
Carne Global Fund Managers (Ireland) Ltd. 0.0469 %	50,059	0.0469 %	21 M CHF
State Street Global Advisors Ltd. 0.0444 %	47,402	0.0444 %	20 M CHF
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	11.02%
Institutional	4.72%
Unknown	84.26%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	11.02%
Switzerland	1.35%
United States	0.95%
United Kingdom	0.49%
Sweden	0.32%
Germany	0.19%
Spain	0.16%
France	0.15%
Ireland	0.13%
Liechtenstein	0.1%
Netherlands	0.1%
Belgium	0.08%
Taiwan	0.07%
Luxembourg	0.07%
Finland	0.07%
Canada	0.07%
New Zealand	0.06%
Norway	0.06%
Austria	0.05%
Italy	0.05%
Portugal	0.05%
South Africa	0.03%
Denmark	0.03%
Australia	0.02%
Singapore	0.02%
Japan	0.02%
Hong Kong	0.01%

Based on 1000 largest holdings

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

07-23 - Earnings release - Q2 2026

More about the company